New Study Provides Further Evidence that Rna Disruption Assay™ (RDA™) May Be Useful Tool In Predicting Clinical Outcome Of Chemotherapy In Breast Cancer Patients

Ontario Industry Updates
Written By Guest User

Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (Toomey et al), conducted under the direction of Dr. Bryan Hennessy of the Beaumont Hospital in Dublin, Ireland,  supports the findings that RDA is an effective prediction tool for which patients will have a higher likelihood of achieving a pathological complete response (pCR) in response to chemotherapy and targeted therapy.

For the full press release, click here

For the Journal Article, click here

Guest User
Previous

OBIO CEO Gail Garland Provides Opening Remarks at MDCC's Strategic Entry into the U.S. MedTech Market Seminar
Next

Pre-CAAP Company: SensOR Medical Featured at U OF T Engineering’s Entrepreneurship Hatchery Demo Day